Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001558370-22-005474
Filing Date
2022-04-14
Accepted
2022-04-14 16:34:15
Documents
11

Document Format Files

Seq Description Document Type Size
1 S-3 tmb-20220414xs3.htm S-3 341452
2 EX-1.2 tmb-20220414xex1d2.htm EX-1.2 262226
3 EX-5.1 tmb-20220414xex5d1.htm EX-5.1 18769
4 EX-5.2 tmb-20220414xex5d2.htm EX-5.2 12110
5 EX-23.1 tmb-20220414xex23d1.htm EX-23.1 3471
6 EX-FILING FEES tmb-20220414xexfilingfees.htm EX-FILING FEES 45292
7 GRAPHIC tmb-20220414xs3007.jpg GRAPHIC 6657
8 GRAPHIC tmb-20220414xs3006.jpg GRAPHIC 11255
9 GRAPHIC tmb-20220414xs3008.jpg GRAPHIC 7204
10 GRAPHIC tmb-20220414xex5d1001.jpg GRAPHIC 5668
11 GRAPHIC tmb-20220414xex5d2001.jpg GRAPHIC 5668
  Complete submission text file 0001558370-22-005474.txt   735303
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

EIN.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-264296 | Film No.: 22827717
SIC: 2834 Pharmaceutical Preparations